OXY — Occidental Petroleum Corporation

As of 2026-09-13 the tape and the sell side are pointed the same way. The stock is up 2.37% over one week, 4.97% over one month, 8.70% over three months and 6.19% over six months, sitting $61.46 against a 52-week band of $38.80-$67.45, i.e. roughly 9% off the high and 58% off the low. The Q2 2026 print (Aug 5) beat consensus EPS by ~30% ($2.40 adjusted vs ~$1.85), delivered $5.1B of operating cash flow, and management raised the dividend 8% to $0.28/quarter while pushing principal debt down toward the $10B target. Sell-side reaction was positive (Wells Fargo high target $79, Barclays $71-$75, Susquehanna $70), though the rating distribution is genuinely mixed - 26 Buys, 23 Holds, 3 Sells - so this is 'constructive,' not 'euphoric.' Note the beta of 0.164 in the data set is not credible for an oil E&P; if you are sizing this as a low-volatility stock, you are sizing it wrong.

The headline trend is an inflection, but it is a noisy and partly manufactured one. From Q3 2023 to Q2 2025, revenue ground down from $7.27B to $6.32B and operating margin compressed from 24.8% to 13.6%; the back half of 2025 was genuinely ugly, with operating margins of 9.3% (Q4 2025) and 7.2% (Q1 2026) and a near-zero Q4 2025 ($102M net income, -$0.069 diluted EPS) following the -$125M Q4 2024 loss. Then Q2 2026 exploded: revenue $8.33B (+31.8% YoY vs $6.32B), operating income $3.78B (+341% YoY), net income $2.98B (+591% YoY), EPS $2.75 vs $0.26. Do not take that at face value. The deterministic score's own note flags a +59% quarter-over-quarter revenue swing from $5.23B to $8.33B as possibly a divestiture/spinoff/major-acquisition artifact, and Q1 2026 shows $3.345B of net income against only $375M of operating income - roughly $3B of non-operating gains (almost certainly the OxyChem disposal) that will never repeat. The clean, reliable trend in this data set is the balance sheet, not the income statement: long-term debt fell from $24.32B (Dec 2024) to $23.38B, $22.71B, $20.21B, $20.43B, then $15.25B (Mar 2026) and $12.80B (Jun 2026), while stockholders' equity rose from $34.16B to $41.75B. FCF is lumpy but real: -$298M in Q1 2026 (the weakest quarter in the window) against $2.707B in Q2 2026, for $5.31B TTM and roughly $4.33B/$4.50B in full-year 2025/2024. Verdict: accelerating cash generation and deleveraging, decelerating reported margin quality through 2025, and a Q2 2026 quarter that should be treated as a peak-condition reading rather than a new run-rate.

Fair, leaning modestly cheap on cash flow and neutral on history. As of 2026-09-13 the stock trades at 9.24x TTM earnings and ~9.7x the $6.308 next-fiscal-year consensus EPS, against a 5-year average P/E of 16.03x and an EV/EBITDA of 5.20x. On price-to-sales it looks expensive - 2.43x versus a 5-year average of 1.61x - but that comparison is distorted because the revenue base in the denominator is mid-restructuring (Q1 2026 revenue of $5.23B looks anomalously low, Q2 2026's $8.33B anomalously high). P/B of 1.47 and debt-to-equity of 0.35 are reasonable for a large-cap E&P. The TTM P/E 'cheapness' is also partly an accounting artifact: TTM EPS is flattered by the ~$3B Q1 2026 non-operating gain. The deterministic model labels valuation 'Neutral vs. its own history,' and that is the right read - you are not paying a premium multiple for peak earnings, but you are also not getting a distressed multiple. The 0.034 PEG ratio is noise for a commodity producer and should be ignored.

The key insight as of 2026-09-13: the market is NOT capitalizing the Q2 2026 blowout. At $61.46 the stock sits at ~9.7x next-FY EPS of $6.308, which is below the trailing ~$6.50 you get by summing the last four reported quarters ($0.65, -$0.069, $3.17, $2.75), even though analysts model revenue growing ~5% to $26.46B. In other words, the sell side is explicitly assuming earnings normalize down from here - which is exactly what you would expect with WTI near $93 and the company realizing $96.78/bbl. This cuts both ways. The upside case: there is no 'priced-for-perfection' risk in the multiple, and if $90+ crude persists, $6.31 of EPS will prove conservative and the stock is genuinely cheap. The downside case: the E is doing more work than the multiple, so a move to $70 WTI likely cuts the forward EPS deck by 30-40% and compresses the multiple at the same time - a double hit. Watch the oil price, not the P/E line.

As of 2026-09-13, OXY's RSI(14) stood at 62.32 - firm momentum, not stretched (below the 70 overbought line). The price was 2.2% above its 20-day SMA (~$60.14), 7.64% above its 50-day (~$57.10), and 16.42% above its 200-day (~$52.79), with the moving averages stacked in textbook uptrend order. The stock is ~9% below the $67.45 52-week high while sitting 58% above the $38.80 low. Timing implication: the trend is intact and shorting into it is a bad idea, but at $61.46 you are buying near the top of the range, not on a dip - there is no margin of safety in the entry price. A pullback toward the 50-day near $57 would offer a materially better risk/reward for new money; the RSI has headroom before it signals an exhaustion move toward $67-$70.

• Crude oil price and geopolitical supply risk: WTI near $93/bbl with Middle East tension and Strait of Hormuz concerns is the single dominant driver. OXY's organic breakeven is estimated below $40, so at $96.78/bbl Q2 realized pricing the cash margin is enormous - but every $10/bbl move is roughly $2.5B of annual revenue and swings the forward EPS deck by a third or more.
• Interest rates and refinancing cost: with rates still elevated, the deleveraging program (LT debt $24.3B in Dec 2024 to $12.8B in Jun 2026, target $10B) is both a value driver and a rate-sensitive one. Reaching the target likely lowers the cost of capital and re-rates the equity.
• OPEC+ supply policy and non-OPEC (Guyana, Brazil, US shale) supply growth: the principal medium-term threat to the price deck. A supply-driven price war would hit OXY's earnings far harder than its balance sheet.
• Carbon-capture and low-carbon policy: OXY is the most DAC-exposed large-cap E&P (Stratos and the Gulf Coast hubs). 45Q incentive changes, permitting reform, or methane regulation directly affect capex plans and returns on a capital-hungry business line with uncertain economics.
• Energy sector rotation and shareholder-return competition: energy's index weight and the market's preference for buybacks over growth capex determine the multiple applied to the same cash flow. OXY's 1.7% yield and 8% dividend raise compete against peers returning far more.

• Q3 2026 earnings, expected early-to-mid November 2026 - the next hard checkpoint on debt reduction toward the $10B target, Permian production run-rate, and any full-year guidance revision.
• Dividend payment of $0.28/share on October 15, 2026 (record date September 10, 2026), the first payout at the newly raised 8% rate - and the prospect of further increases if FCF holds.
• Reaching the $10B principal debt target, which management has framed as the trigger for shifting capital allocation decisively toward buybacks and dividends. Crossing that line would be a genuine re-rating event.
• Oil price path and Middle East escalation - upside optionality if supply risk persists; the single biggest swing factor in either direction.
• Post-OxyChem portfolio simplification - further asset sales or JV monetizations would accelerate deleveraging and add credibility to the $10B target timeline.

• Oil price collapse: at $70 WTI, the $6.308 forward EPS deck likely gets cut 30-40%, and the multiple compresses at the same time. There is no business-model hedge for this.
• Earnings quality and one-off distortion: Q1 2026 posted $3.345B of net income on only $375M of operating income - roughly $3B of non-operating gain, most likely the OxyChem disposal. TTM P/E of 9.24x and TTM EPS are flattered by items that do not repeat, and the deterministic score's own note flags the +59% QoQ revenue swing as a structural artifact.
• Structurally low returns on capital: trailing ROIC of 3.2% and ROE of 6.6% sit uncomfortably against a 23.0% operating margin and 28.8% net margin, implying a very large, low-return asset and equity base. If returns do not improve, the old 16x average P/E is not coming back.
• Leverage still above peers and above the company's own target: $12.8B of long-term debt with $4.15B of cash means net debt is real. A downturn before the $10B target is reached forces an ugly choice between the dividend, capex, and debt paydown.
• Low-carbon/DAC execution: carbon capture is capital-intensive, technically demanding, and returns are unproven at scale. Money spent there is money not spent on debt reduction or buybacks, and a project stumble would be read as capital-allocation failure.

Yes, OXY is a reasonable hold-to-buy here, but be honest about what you own: a levered oil-price call wrapped in a deleveraging story, not a compounder. The math is compelling - $5.31B of TTM free cash flow against a $61.1B market cap is an 8.7% FCF yield, long-term debt has fallen from $24.3B to $12.8B in eighteen months with a $10B target in sight, the dividend was just raised 8%, and the stock trades at 9.2x trailing and ~9.7x forward earnings with zero premium being paid for the Q2 2026 blowout. The offset is that those numbers were earned at $93-$97 oil, trailing EPS is inflated by a ~$3B one-off gain, and analysts' own next-FY EPS estimate of $6.308 is below trailing - the forward deck already assumes normalization. Buy it as a cash-return and balance-sheet-improvement play with oil upside optionality, size it as a cyclical, and don't chase above the low-to-mid $60s.

Blended two independent methods as of 2026-09-13: 70% weight to 11.0x consensus next-FY EPS of $6.308 (= $69.39), a mid-cycle multiple for a levered, commodity-price-taking large-cap E&P that sits above OXY's current 9.7x forward P/E but well below its 16.03x 5-year average; and 30% weight to an 8.5% required FCF yield on normalized free cash flow of $5.0B (a haircut from the $5.31B TTM figure to strip out $93 WTI pricing), which values the ~994.6M shares at ~$59.14. Weighted blend: (0.7 x $69.39) + (0.3 x $59.14) = $66.31, implying roughly 8% upside from the $61.46 price and slightly below the $70.40 sell-side consensus.